




# State of Louisiana

Louisiana Department of Health  
Bureau of Health Services Financing

## MEMORANDUM

**DATE:** March 25, 2022

**TO:** All Louisiana Medicaid Prescribing Providers and Pharmacists

**FROM:** Patrick Gillies, Medicaid Executive Director 

**SUBJECT:** Louisiana Medicaid Pharmacy Point of Sale (POS) Therapeutic Duplication- April 2022

Effective April 1, 2022, the Louisiana Medicaid Fee for Service (FFS) Pharmacy Program and Managed Care Organizations (MCOs), in consultation with the Drug Utilization Review (DUR) Board, will implement therapeutic duplication (TD) at Point of Sale (POS) for select medications. The therapeutic duplication edits apply to pharmacy claims submitted to FFS and MCOs (Aetna, AmeriHealth Caritas, Healthy Blue, Louisiana Healthcare Connections, and UnitedHealthcare).

**Point of Sale (POS) Therapeutic Duplication of Serdexmethylphenidate/  
Dexmethylphenidate (Azstarys™) with Another Long-Acting ADD/ADHD Medication**

An incoming pharmacy claim for serdexmethylphenidate/dexmethylphenidate (Azstarys™) will deny with a therapeutic duplication if there is an active claim for another long-acting ADD/ADHD medication on file. Conversely, a claim for long-acting ADD/ADHD medication will deny with a therapeutic duplication if there is an active claim for serdexmethylphenidate/dexmethylphenidate (Azstarys™) on file.

**Point of Sale (POS) Therapeutic Duplication of Serdexmethylphenidate/  
Dexmethylphenidate (Azstarys™) with Another Short-Acting ADD/ADHD Medication**

An incoming pharmacy claim for serdexmethylphenidate/dexmethylphenidate (Azstarys™) will deny with a therapeutic duplication if there is an active claim for another short-acting ADD/ADHD medication on file. Conversely, a claim for short-acting ADD/ADHD medication will deny with a therapeutic duplication if there is an active claim for serdexmethylphenidate/dexmethylphenidate (Azstarys™) on file.

**Therapeutic Duplication of Olanzapine/Samidorphan (Lybalvi™) with Another Oral Antipsychotic Medication**

An incoming pharmacy claim for olanzapine/samidorphan (Lybalvi™) will deny with a therapeutic duplication if there is an active claim for another oral antipsychotic medication on file. Conversely, a claim for another oral antipsychotic medication will deny with a therapeutic duplication if there is an active claim for olanzapine/samidorphan (Lybalvi™) on file.

**Point of Sale (POS) Therapeutic Duplication of Paliperidone Palmitate (Invega Hafyera™) with Another Injectable Antipsychotic Medication**

An incoming pharmacy claim for paliperidone palmitate (Invega Hafyera™) will deny with a therapeutic duplication, if there is an active claim for another injectable antipsychotic medication on file. Conversely, a claim for another injectable antipsychotic medication will deny with a therapeutic duplication, if there is an active claim for paliperidone palmitate (Invega Hafyera™) on file.

**Point of Sale (POS) Therapeutic Duplication of Lorazepam (Loreev XR™) with Another Anxiolytic Medication**

An incoming pharmacy claim for lorazepam (Loreev XR™) will deny with a therapeutic duplication if there is an active claim for another anxiolytic medication. Conversely, a claim for another anxiolytic medication will deny with a therapeutic duplication if there is an active claim for lorazepam (Loreev XR™).

**Point-of-Sale (POS) Therapeutic Duplication Denial Codes and Override Procedure**

Pharmacy claims with a therapeutic duplication will deny at POS with:

MCO Only: The pharmacy claim will deny with a **NCPDP rejection code**. If additional assistance is needed, contact the health plan (See contact information at the end of this document).

FFS Only: **NCPDP rejection code 88** (DUR reject code) mapped to **EOB code 482** (Therapeutic Duplication).

After consultation with the prescriber, the pharmacist may override the therapeutic duplication denial. This consultation is necessary to confirm that the (1) prescriber is aware of the current claim and/or (2) the addition of a second agent is necessary (i.e. change in therapy). The pharmacist may submit the following codes at POS to override the claim denial, if the prescriber deems the therapeutic duplication medically necessary:

**NCPDP 439-E4 field** (Reason for Service Code) – **TD** (Therapeutic Duplication)

**NCPDP 440-E5 field** (Professional Service Code) – **M0** (Prescriber Consulted)

**NCPDP 441-E6 field** (Result of Service Code) – **1G** (Filled with Prescriber Approval)

**Additional Information:**

**FFS Only:** Most pharmacy claim denials can be overridden in emergency situations at Point of Sale. If it is necessary to override the claim, “03” can be entered in **NCPDP field 418-DI** (Level of Service). Refer to [www.lamedicaid.com](http://www.lamedicaid.com) for the POS User Guide for drug specific override procedures.

**MCO Only:** If an override is required, or additional assistance needed, contact the health plan. (See contact information at the end of this document.)

Refer to <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf> for the PDL, which is inclusive of the *Louisiana Uniform Prescription Drug Prior Authorization Form*, medication list, and clinical criteria.

If you have questions about the content of this memo, you may contact the FFS pharmacy help desk by phone at (800) 437-9101.

If you have questions about pharmacy claims billing, you may contact the appropriate plan at their pharmacy help desk listed in the chart below.

<b>Healthcare Provider</b>	<b>Pharmacy Help Desk</b>	<b>Pharmacy Help Desk Phone Number</b>
Aetna	CVS Health	(855) 364-2977
AmeriHealth Caritas	PerformRx	(800) 684-5502
Fee for Service	Gainwell Technologies	(800) 648-0790
Healthy Blue	CVS	(833) 236-6194
Louisiana Healthcare Connections	CVS Caremark	(800) 311-0543
UnitedHealthcare	Optum Rx	(866) 328-3108

Please forward this notice to other providers to assist with notification. Your continued cooperation and support of the Louisiana Medicaid Program efforts to coordinate care and improve health are greatly appreciated.

PG/MBW/GJS

- c: Healthy Louisiana Plans
- Melwyn B. Wendt
- Gainwell Technologies